A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Avelumab (Primary) ; Irinotecan; Paclitaxel
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms JAVELIN Gastric 300
  • Sponsors EMD Serono
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 30 Sep 2022 to 20 Sep 2022.
    • 08 Aug 2017 Planned primary completion date changed from 31 Aug 2017 to 14 Sep 2017.
    • 03 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top